Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.
The PRoFeSs score―which includes the Charlson score, as well as levels of day 3 lactate, day 1 and day 3 procalcitonin, day 3 D-dimer, and day 1 brain-type natriuretic peptide―can identify severe community-acquired pneumonia patients at high risk of poor outcomes 5 days after ICU admission, a recent study has found.
Assoc Prof Philip Eng, senior consultant respiratory physician at Mt Elizabeth Hospital in Singapore, shares his insights with Pearl Toh on diagnosing and managing pneumonia in the primary care setting.
The novel pleuromutilin antibiotic lefamulin - now in an oral therapy form - has demonstrated a favourable safety and tolerability profile for community-acquired bacterial pneumonia (CABP) in the LEAP* 2 study, the same result seen for intravenous (IV) lefemulin in the original LEAP 1 study.
The tetracycline omadacycline is not inferior to moxifloxacin when used as empirical monotherapy for hospitalized adults with community-acquired bacterial pneumonia, according to the results of a phase III study.
Individuals hospitalized with pneumonia have an elevated risk of developing major adverse cardiovascular events (MACE), with a greater risk among those with bacterial compared with viral pneumonia, according to a recent study presented at AHA 2018.
The pneumonia-causing bacteria, Streptococcus pneumoniae (pneumococcus), can be spread through nose picking and rubbing after exposure of the hands to the bacteria — in addition to the conventionally known route of inhalation of airborne droplets, a study reveals.
New drug applications approved by US FDA as of 1 - 15 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 01 - 15 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Long-term proton-pump inhibitor (PPI) therapy was associated with an increased pneumonia risk among older adults, putting to rest the controversies about the validity of previously reported short-term harms of PPIs, according to a large, longitudinal analysis of electronic medical records.
Individuals with obesity are at an elevated risk of developing infections, particularly that of the skin in both men and women, and those of the gastrointestinal and urinary tracts and sepsis in women only, according to a study.
An increase in intensive care unit (ICU) management and bacterial pneumonia development occurs in children with special risk medical conditions (SRMC), but a rise in the probability of death or need for mechanical ventilation remains inconsistent, suggests a recent study.
Oral amoxicillin–clavulanate effectively promotes resolution of nonsevere acute exacerbations in children with non-cystic
fibrosis (CF) bronchiectasis, thus confirming the role of amoxicillin–clavulanate as first-line treatment for bronchiectasis, according to results from the three-arm BEST-1 study.